US › Healthcare

Vor Biopharma Inc (VOR)

US · Healthcare · Biotechnology

$22.25+3.92%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-219.6M
Profit YoY
-575.9%
EPS
$-0.73
EPS estimate
$-0.78

EPS came in at -0.73 against a street estimate of -0.78 — a beat of 6.4%.

Key statistics

Market cap
$1.15B
Forward P/E
0.0
P/B
0.66
Book value
$-2.78
EPS (TTM)
$-70.40
52-week high
$50.20
52-week low
$6.50
50-day MA
$16.75
200-day MA
$15.52
Beta
1.70

Analyst view

Analysts rate Vor Biopharma Inc a hold (0 buy, 5 hold, 0 sell out of 5) with an average price target of $37.88.

Shareholding

Insiders
4.27%
Institutions
75.28%

Largest institutional holders

FundStake
TCG Crossover Management, LLC10.47%
RA Capital Management, LLC9.97%
FCPM III SERVICES BV7.60%
VR Adviser, LLC5.61%
Frazier Life Sciences Management, L.P.4.69%
Caligan Partners LP3.55%
Paradigm Biocapital Advisors LP3.23%
Great Point Partners LLC3.23%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Vor Biopharma Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.